Article
BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
The American journal of surgical pathology - 1 Apr 2015
Kleinschmidt-DeMasters Bette K, Aisner Dara L, Foreman Nicholas K
Abstract excerpt
Epithelioid glioblastomas (E-GBMs) manifest BRAF V600E mutation in up to 50% of cases, compared with a small percentage of ordinary GBMs, suggesting that they are best considered variants rather than a different pattern of GBM. Availability of a targeted therapy, vemurafenib, may make testing BRAF status important for treatment. It is unclear whether BRAF VE1 immunohistochemistry (IHC) can substitute for Sanger...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Biomarkers, Tumor
- Brain Neoplasms
- Child
- DNA Mutational Analysis
- Epithelioid Cells
- Female
- Genetic Predisposition to Disease
- Glioblastoma
- Humans
- Immunohistochemistry